3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Status
Completed
3
Active not recruiting
1
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
3
Conditions
Pancreatic Neoplasms
70
Breast Neoplasms
64
Neoplasms
35
Carcinoma, Non-Small-Cell Lung
29
Neoplasm Metastasis
20
Triple Negative Breast Neoplasms
18
Lung Neoplasms
13
Ovarian Neoplasms
12
Adenocarcinoma
12
Stomach Neoplasms
10
Squamous Cell Carcinoma of Head and Neck
10
Melanoma
10
Head and Neck Neoplasms
8
Fallopian Tube Neoplasms
7
Cholangiocarcinoma
7
Urinary Bladder Neoplasms
6
Recurrence
6
Esophageal Neoplasms
6
Digestive System Neoplasms
5
Colorectal Neoplasms
5
Carcinoma, Ovarian Epithelial
5
Uterine Cervical Neoplasms
4
Sarcoma, Ewing
4
Sarcoma
4
Prostatic Neoplasms
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Pancreatic Diseases
4
Inflammatory Breast Neoplasms
4
Gallbladder Neoplasms
4
Endocrine Gland Neoplasms
4
Interventions
Paclitaxel
6
Carboplatin
6
Radiotherapy
5
Chemotherapy, Adjuvant
5
Cyclophosphamide
4
Trastuzumab
3
Tamoxifen
3
Letrozole
3
Doxorubicin
3
Brachytherapy
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
pertuzumab
2
Surgical Procedures, Operative
2
Radiotherapy, Conformal
2
Magnetic Resonance Spectroscopy
2
Epirubicin
2
talimogene laherparepvec
1
sargramostim
1
palbociclib
1
ferric carboxymaltose
1
atezolizumab
1
atamestane
1
aldesleukin
1
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
1
VPS Coriolus versicolor extract
1
Toremifene
1
Thiotepa
1
Therapeutics
1
Reverse Transcriptase Polymerase Chain Reaction
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Ductal, Breast
×
Albumin-Bound Paclitaxel
×
Clear all
NCT02620280
2024-03-06
NeoTRIPaPDL1
Fondazione Michelangelo
Phase 3
Completed
278 enrolled
NCT02682693
2021-02-02
GeparX
GBG Forschungs GmbH
Phase 2
Completed
780 enrolled
NCT01583426
2020-08-06
GeparSepto
GBG Forschungs GmbH
Phase 3
Completed
1,229 enrolled